

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

February 07, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D. C. 20549

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 27, 2003

**IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-29993**

(Commission File No.)

**94-3200380**

(IRS Employer Identification No.)

**1255 Terra Bella Avenue  
Mountain View, California 94043**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

---

**TABLE OF CONTENTS**

Item 5. Other Events

Item 7. Financial Statements and Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events**

On February 6, 2003, IntraBiotics Pharmaceuticals, Inc. (the Company) announced that it entered into an agreement to sell, subject to stockholder approval of the transaction and certain other conditions, up to \$3.5 million of shares of Series A Convertible Preferred Stock and Warrants to purchase shares of Common Stock of the Company.

In addition, the Company announced that on January 27, 2003, Henry J. Fuchs, M.D., the Company's President and Chief Operating Officer, was elected the Chief Executive Officer by the Board of Director. Ernest Mario, Ph.D., the Company's former Chief Executive Officer, will remain Chairman of the Company's Board of Directors.

Further, on January 27, 2003, the Board of Directors of IntraBiotics approved, and on February 6, 2003, the Company completed the Option Cancellation and Regrant Program, whereby all optionholders, including the Company's employees, officers and directors, could elect to have their existing, outstanding options cancelled in exchange for new options to purchase the same number of shares, subject to some exceptions, which were granted immediately following the cancellation of the existing options.

**Item 7. Financial Statements and Exhibits**

**(c) Exhibits.**

- 99.1 Press Release, dated February 6, 2003, entitled IntraBiotics to Launch Phase II/III Clinical Study of Iseganan HCl for Ventilator-Associated Pneumonia (VAP).

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**INTRABIOTICS PHARMACEUTICALS, INC.**

Dated: February 6, 2003

By: /s/ Eric H. Bjerkholt

---

Eric H. Bjerkholt  
Sr. Vice President and  
Chief Financial Officer

**Table of Contents**

**INDEX TO EXHIBITS**

- 99.1 Press Release, dated February 6, 2003, entitled IntraBiotics to Launch Phase II/III Clinical Study of Iseganan HCl for Ventilator-Associated Pneumonia (VAP).